Healthcare - Oncology
Companies developing cancer therapeutics, diagnostics, and precision oncology tools
Immunotherapy & Immuno-Oncology78
Targeted Therapy & Precision Oncology95
Cell & Gene Therapy for Cancer35
Radiopharmaceuticals & ADCs11
Cancer Diagnostics & Biomarkers28
 LLY | Eli Lilly & Co. | Targeted Therapy & Precision Oncology | $1.0t | $1150.50 | -0.3% | 7.1K |
 JNJ | Johnson & Johnson | Immunotherapy & Immuno-Oncology | $0.7t | $268.93 | -0.7% | 6.2K |
 ABBV | ABBVIE INC. | Immunotherapy & Immuno-Oncology | $462.5b | $263.04 | -0.5% | 3.2K |
 MRK | Merck & Co., Inc. | Immunotherapy & Immuno-Oncology | $375.8b | $146.55 | -0.5% | 11.9K |
 AZN | AstraZeneca PLC | Immunotherapy & Immuno-Oncology | $250.7b | $167.27 | +0.5% | 49.2K |
 AMGN | Amgen Inc | Immunotherapy & Immuno-Oncology | $239.4b | $379.49 | 0.0% | 4.7K |
 GILD | Gilead Sciences Inc | Cell & Gene Therapy for Cancer | $185.5b | $150.10 | 0.0% | 5.1K |
 BMY | Bristol-Myers Squibb Co. | Immunotherapy & Immuno-Oncology | $138.2b | $62.95 | -0.3% | 17.1K |
 REGN | Regeneron Pharmaceuticals Inc | Immunotherapy & Immuno-Oncology | $86.8b | $784.97 | 0.0% | 526 |
 MRNA | Moderna, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $59.4b | $158.75 | 0.0% | 268.7K |
 NTRA | Natera, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $47.2b | $363.84 | 0.0% | 4.0K |
 RVMD | Revolution Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $45.2b | $196.53 | 0.0% | 637 |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Immunotherapy & Immuno-Oncology | $28.4b | $58.85 | 0.0% | 3.3K |
 INCY | Incyte Genomics Inc | Targeted Therapy & Precision Oncology | $26.1b | $126.38 | 0.0% | 1.8K |
 GH | Guardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $21.9b | $178.09 | 0.0% | 1.5K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Targeted Therapy & Precision Oncology | $15.9b | $244.50 | 0.0% | 1.8K |
 EXEL | Exelixis Inc | Targeted Therapy & Precision Oncology | $14.5b | $58.45 | 0.0% | 10.4K |
 HALO | Halozyme Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $12.4b | $110.00 | 0.0% | 13.2K |
 CORT | Corcept Therapeutics Inc. | Targeted Therapy & Precision Oncology | $11.9b | $115.71 | 0.0% | 2.8K |
 NUVL | Nuvalent, Inc. Class A Common Stock | Targeted Therapy & Precision Oncology | $9.8b | $123.96 | 0.0% | N/A |
 IBRX | ImmunityBio, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $8.4b | $8.46 | 0.0% | 71.8K |
 CAI | Caris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $7.0b | $30.82 | 0.0% | 14.6K |
 ACLX | Arcellx, Inc. Common Stock | Immunotherapy & Immuno-OncologyCell & Gene Therapy for Cancer | $6.7b | $115.06 | -0.0% | 16.1M |
 CGON | CG Oncology, Inc. Common stock | Immunotherapy & Immuno-Oncology | $6.6b | $75.64 | 0.0% | 1.1K |
 LNTH | Lantheus Holdings, Inc | Radiopharmaceuticals & ADCs | $6.6b | $101.00 | 0.0% | 9.2K |
 COGT | Cogent Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $6.0b | $32.94 | 0.0% | 14.6K |
 ERAS | Erasca, Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.7b | $15.06 | 0.0% | 2.7K |
 CELC | Celcuity Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.7b | $85.36 | 0.0% | 347 |
 BLLN | BillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & Biomarkers | $4.5b | $110.70 | 0.0% | 1.9K |
 ELVN | Enliven Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.2b | $50.40 | 0.0% | 451 |
 RLAY | Relay Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.2b | $19.43 | 0.0% | 3.2K |
 ADPT | Adaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $3.9b | $28.67 | 0.0% | 5.6K |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | Immunotherapy & Immuno-OncologyCell & Gene Therapy for Cancer | $3.9b | $10.11 | 0.0% | 140.1K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.9b | $38.82 | 0.0% | 109 |
 TNGX | Tango Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $3.8b | $23.25 | 0.0% | 256 |
 RCUS | Arcus Biosciences, Inc. | Immunotherapy & Immuno-Oncology | $3.8b | $25.84 | +0.6% | 11.3K |
 ABCL | AbCellera Biologics Inc. Common Shares | Radiopharmaceuticals & ADCs | $3.7b | $12.73 | 0.0% | 80.7K |
 GRAL | GRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $3.6b | $79.55 | 0.0% | 908 |
 VCYT | Veracyte, Inc. | Cancer Diagnostics & Biomarkers | $3.6b | $40.29 | 0.0% | 937 |
 IMNM | Immunome, Inc. | Radiopharmaceuticals & ADCsTargeted Therapy & Precision Oncology | $3.1b | $23.93 | 0.0% | 3.6K |
 SLS | SELLAS Life Sciences Group, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $2.8b | $11.46 | 0.0% | 34.0K |
 NRIX | Nurix Therapeutics, Inc. Common stock | Targeted Therapy & Precision Oncology | $2.6b | $25.60 | 0.0% | 9.5K |
 NKTR | Nektar Therapeutics | Immunotherapy & Immuno-Oncology | $2.6b | $68.75 | 0.0% | 2.6K |
 PGEN | Precigen, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $2.6b | $7.87 | 0.0% | 7.1K |
 NUVB | Nuvation Bio Inc. | Targeted Therapy & Precision Oncology | $2.4b | $6.09 | +0.5% | 1.1K |
 BHVN | Biohaven Ltd. | Targeted Therapy & Precision Oncology | $2.4b | $13.84 | +0.8% | 12.2K |
 NEO | NeoGenomics, Inc. | Cancer Diagnostics & Biomarkers | $2.2b | $19.80 | 0.0% | 11.9K |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.2b | $21.52 | -0.0% | 3.0M |
 URGN | UroGen Pharma Ltd. Ordinary Shares | Targeted Therapy & Precision Oncology | $2.2b | $44.03 | 0.0% | 289 |
 ZYME | Zymeworks Inc. | Targeted Therapy & Precision Oncology | $2.1b | $27.59 | 0.0% | 2.7K |